Congratulations Dr @BiagioRicciutMD for being an awardee of #40under40 in cancer as an emerging leader. I am very grateful to be a witness of your continuous contribution to cancer research & patient care with such a high level of commitment Dana-Farber #ASCO23 #proud

Check out our paper on Science Translational Medicine that deciphers how to overcome ALK TKIs resistance in ALK+ lymphoma by targeting the CCR7-PI3Kgamma pathway. Congrats to all the talented scientists that helped the work! It's on the cover! Boston Children's Università di Torino science.org/toc/stm/15/702

Glad to see our collaborative effort on the predictors of long-term response to #ICI in #NSCLC out in Clinical Cancer Research today! W/⭐️ investigators Rohit Thummalapalli Natalie Vokes Adam J. Schoenfeld Mark Awad João Alessi, MD @ArielleElkrief Alessandro Di Federico Giuseppe Lamberti Federica Pecci OncoAlert #LCSM

“A good #mentor is someone who has more imagination about you than you have about yourself”. There’s no better description for my former mentor Prof Crinò. It was wonderful to share the stage with him years later, discussing resistance mechanisms to targeted therapies in #NSCLC.

The Chiarle lab is at #AACR2024. Come to see our posters N.21, N.50, N.403 and N.404 today from 1:30 to 5:00pm Carmen Mecca Elisa Bergaggio Jianli Tao Taek-Chin Cheong Chiarle lab Boston Children's

In a new study published in JTO & JTO CRR IASLC, @BiagioRicciutMD and @danafarber researchers showed improved long-term survival with pembrolizumab & cemiplimab in NSCLC patients with PD-L1 >90% vs 50-89%. #LCSM Read more here: ms.spr.ly/6010YyynQ

Had a great time and insightful discussions at #RomeLung24 reviewing biomarkers for #ICI efficacy in #NSCLC. w/ a stellar faculty Jordi Remon Solange Peters Francesco Christian Rolfo, Tony Mok Stephen V Liu, MD, Fred R. Hirsch Federico Cappuzzo Roberto Ferrara Benjamin Besse &

Comprehensive mutational scanning of #EGFR reveals TKI sensitivities of extracellular domain mutants. shorturl.at/lrI45 🧬Multiple EGFR extracellular domain variants, not associated with approved targeted therapies, were sensitive to afatinib and dacomitinib in vitro.

Congratulations to @danafarber BiagioRicciuti, MD, PhD (Biagio Ricciuti, MD PhD) who is a recipient of the IASLC 2024 Young Investigator Grant for his work: Targeting KRAS amplification as a de novo oncogene driver alteration in non-small cell lung cancer. More▶️ms.spr.ly/6011YfYmB

Introducing our final round of keynote speakers for #ILCS24! We're thrilled to have Biagio Ricciuti, MD PhD, Anne Schultheis, Roberto Ferrara and Nuria Novoa speak at the upcoming ILCS. Join them in Lausanne or virtually to discuss the latest insights in #LungCancer treatment ⬇️

The OncoAlert newsletter is out. 📫 Don't miss this week updates, including: 🦠Intratumoral Escherichia and⬆️ #ICI efficacy in #NSCLC 💊Tox w/#ICI & Target tx in #NSCLC ❌Cancer misinformation in #SoMe & more Registration link: oncoalert.m-pages.com/nhMpwe/oncoale…

🚨Our collaborative effort uncovering in vivo vulnerabilities to #GPX4 and #HDAC inhibitors in 💊drug-persistent vs. drug-resistant #BRAF V600E #lung adenocarcinoma 🫁 is out in Cell Reports Medicine! W/Santamaria’s Lab & AmbrogioLab Link: sciencedirect.com/science/articl… Dana-Farber News #LCSM

T Cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) +/- Pembrolizumab (KEYNOTE-603). Cancer Discovery. 🚨OncoAlert 🏥 Phase I, resected #NSCLC & #melanoma 💊No grade 4/5 AEs ✅Neoantigen-specific T cell responses and expansion after combo doi.org/10.1158/2159-8…

Sharing our latest effort out in Clinical Cancer Research! This multicenter study identified a #KEAPness signature that outperforms deleterious #KEAP1 mutations in predicting #ICI efficacy in #NSCLC. A step forward in understanding transcriptional phenocopies of KEAP1 mutations. 🧵1/9

Out in Nature Communications our collaborative effort showing how adaptive mechanisms & increased GTP loading confer resistance to #KRAS G12C OFF 💊. Selective inhibitor RMC-4998 targeting GTP-bound (ON) KRAS can overcome resistance. W/ AmbrogioLab OncoAlert nature.com/articles/s4146…

Engaging presentations at #Presidential Symposium III: Eyes to the Future at #ESMO24 w/Andrea Botticelli Cigall Kadoch Adrian Sacher, M.D. FabriceAndre Nadia Harbeck,MD PhD. Thx ESMO - Eur. Oncology for the opportunity to discuss the PIOneeR trial by Pascale Tomasini & team. We need more biomarker driven and

NVL-655: 4th-generation, #ALK-selective TKI w/ CNS penetration targeting diverse #ALK-mutant oncoproteins, including lorlatinib-resistant compound mutations. ✅>50-fold selectivity for ALK over 96% of the kinome tested & brain penetrant ✅≥100-fold⬆️ potency against ALK G1202R

Today we launch the PoweRD 2 Cure ALK+ Lung Cancer TeamLab! Uniting researchers from Dana-Farber MD Anderson Cancer Center Koch Institute at MIT Sidney Kimmel Comprehensive Cancer Center Memorial Sloan Kettering Cancer Center Boston Children's Mass General Cancer Center CU Cancer Center @VUMC_Cancer in radical collaboration to target residual lung

Don't lose the opportunity to see Biagio Ricciuti, MD, PhD in a suit and a tie here at Room E450a. A last push in the last day of this amazing #ASCO25

What about the rare stuff? Biagio Ricciuti, MD, PhD sheds light in what to do in patients with AGAs that could potentially respond to IO, such as MET, BRAF and KRAS. And it would not be Biagio without an opinion on STK11/KEAP1 co-mutations. #ASCO25